Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Lung Cancer

FDA Grants Approval to Trastuzumab Deruxtecan for HER2 Lung Cancer

Posted on August 15, 2022
Post Views: 352

Lung CancerLung cancer patients now have another treatment option. For those tumors carrying HER2 mutations, can now be treated with trastuzumab deruxtecan. This drug is already approved for use in HER2-positive breast cancer and gastric cancer. Now, it has been approved by the US Food and Drug Administration (FDA) for use in HER2-positive lung cancer. This approval of trastuzumab deruxtecan in non-small cell lung cancer is an important milestone for patients and oncology community. The approval of first HER2-directed treatment option validates HER2 as an actionable target in lung cancer.

Trastuzumab deruxtecan was examined at a dose of 6.4 mg/kg across several trials and as at a dose of 5.4 mg/kg in a randomized dose-finding trial. In 152 patients treated with trastuzumab deruxtecan 5.4mg/kg or 6.4mg/kg, the ORR 57.7% in patients with previously treated unresectable or metastatic non-squamous HER2-mutant NSCLC. The complete response rate observed with trastuzumab deruxtecan was 1.9%. The most common adverse reactions were nausea, decreased white blood cell count, decreased platelet count, increased aspartate aminotransferase, fatigue, decreased appetite etc.

Dave Fredrickson, executive vice president, Oncology Business Unit, AstraZeneca, said in the press release, “HER2-mutant non-small cell lung cancer is an aggressive form of disease which commonly affects young patients who have faced limited treatment options and a poor prognosis to date. Today’s news provides these patients with the opportunity to benefit from a targeted therapy and highlights the importance of testing for predictive markers, including HER2 in lung cancer, at the time of diagnosis to ensure patients receive the most appropriate treatment for their specific disease.”

With this approval, Trastuzumab deruxtecan is now the first HER2-directed therapy approved for patients with previously treated HER2-mutant metastatic non-small cell lung cancer. Also, FDA granted approval to the Oncomine Dx Target Test and Guardant360 CDx as companion diagnostics to detect HER2 mutations in patients with metastatic NSCLC.

The information shared in this blog is for educational purposes only. You should consult your healthcare professional for any medical issues.

Subscribe to our newsletter or follow us on Twitter or Facebook today and never miss an update!

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,322)
  • Lung Cancer: Symptoms and Treatment (5,655)
  • What is Non-Small-Cell Lung Cancer? (5,551)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • Study: Wildfire Smoke Exposure Affects Lung Cancer Survival June 2, 2025
  • Predicting Lung Cancer Risk with AI based Deep Learning Model May 26, 2025
  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d